Head and Neck Cancer

Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Urinary, Pancreas, Phase I, Urinary BladderA Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors
Lip, Oral Cavity and PharynxA Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma
Lip, Oral Cavity and PharynxA Multi-center, Randomized, Open-label, Parallel-group, Phase 2 Study to Evaluate the Efficacy and Safety of VS-101 in Combination With Chemoradiotherapy (CRT) in Patients With Head and Neck Cancer
Cervix, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Lung, Phase I, Rectum, Small Intestine, Stomach, ThyroidA Phase 1, Open-label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB168 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Malignancies
Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, Skin, Urinary BladderAn Open-Label, Phase 1 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AB821 in Adult Participants With Locally Advanced or Metastatic Melanoma and Other Solid Tumors